Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
AEZS's Cash to Debt is ranked higher than
97% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. AEZS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
AEZS' s 10-Year Cash to Debt Range
Min: 0.76  Med: 79.49 Max: No Debt
Current: No Debt
Equity to Asset 0.31
AEZS's Equity to Asset is ranked lower than
84% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. AEZS: 0.31 )
Ranked among companies with meaningful Equity to Asset only.
AEZS' s 10-Year Equity to Asset Range
Min: -0.1  Med: 0.34 Max: 0.97
Current: 0.31
-0.1
0.97
Interest Coverage No Debt
AEZS's Interest Coverage is ranked higher than
95% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AEZS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AEZS' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -6.37
M-Score: 56.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -42559.72
AEZS's Operating margin (%) is ranked lower than
97% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. AEZS: -42559.72 )
Ranked among companies with meaningful Operating margin (%) only.
AEZS' s 10-Year Operating margin (%) Range
Min: -339954.55  Med: -89.30 Max: -8.58
Current: -42559.72
-339954.55
-8.58
Net-margin (%) -24256.07
AEZS's Net-margin (%) is ranked lower than
96% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. AEZS: -24256.07 )
Ranked among companies with meaningful Net-margin (%) only.
AEZS' s 10-Year Net-margin (%) Range
Min: -150581.82  Med: -25.48 Max: 110.36
Current: -24256.07
-150581.82
110.36
ROE (%) -159.03
AEZS's ROE (%) is ranked lower than
88% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. AEZS: -159.03 )
Ranked among companies with meaningful ROE (%) only.
AEZS' s 10-Year ROE (%) Range
Min: -703.16  Med: -8.56 Max: 125.8
Current: -159.03
-703.16
125.8
ROA (%) -39.07
AEZS's ROA (%) is ranked lower than
62% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. AEZS: -39.07 )
Ranked among companies with meaningful ROA (%) only.
AEZS' s 10-Year ROA (%) Range
Min: -57.37  Med: -8.21 Max: 11.16
Current: -39.07
-57.37
11.16
ROC (Joel Greenblatt) (%) -2246.06
AEZS's ROC (Joel Greenblatt) (%) is ranked lower than
71% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. AEZS: -2246.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AEZS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1671.14  Med: -65.84 Max: -14.06
Current: -2246.06
-1671.14
-14.06
Revenue Growth (3Y)(%) -100.00
AEZS's Revenue Growth (3Y)(%) is ranked lower than
90% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. AEZS: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AEZS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -22.75 Max: 131.6
Current: -100
0
131.6
EBITDA Growth (3Y)(%) -40.20
AEZS's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. AEZS: -40.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AEZS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -19.25 Max: 184.7
Current: -40.2
0
184.7
EPS Growth (3Y)(%) -42.50
AEZS's EPS Growth (3Y)(%) is ranked lower than
88% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. AEZS: -42.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AEZS' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -15.00 Max: 65.1
Current: -42.5
0
65.1
» AEZS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AEZS Guru Trades in Q2 2014

Jim Simons 641,917 sh (+1353.95%)
» More
Q3 2014

AEZS Guru Trades in Q3 2014

Jim Simons Sold Out
» More
Q4 2014

AEZS Guru Trades in Q4 2014

Jim Simons 15,800 sh (New)
» More
Q1 2015

AEZS Guru Trades in Q1 2015

Jim Simons 563,700 sh (+3467.72%)
» More
» Details

Insider Trades

Latest Guru Trades with AEZS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.81
AEZS's P/B is ranked higher than
95% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. AEZS: 0.81 )
Ranked among companies with meaningful P/B only.
AEZS' s 10-Year P/B Range
Min: 0.63  Med: 1.62 Max: 43.4
Current: 0.81
0.63
43.4
EV-to-EBIT 0.78
AEZS's EV-to-EBIT is ranked higher than
95% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. AEZS: 0.78 )
Ranked among companies with meaningful EV-to-EBIT only.
AEZS' s 10-Year EV-to-EBIT Range
Min: -199.8  Med: -1.20 Max: 24
Current: 0.78
-199.8
24
Current Ratio 4.78
AEZS's Current Ratio is ranked higher than
53% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. AEZS: 4.78 )
Ranked among companies with meaningful Current Ratio only.
AEZS' s 10-Year Current Ratio Range
Min: 1.33  Med: 3.36 Max: 33.17
Current: 4.78
1.33
33.17
Quick Ratio 4.78
AEZS's Quick Ratio is ranked higher than
55% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. AEZS: 4.78 )
Ranked among companies with meaningful Quick Ratio only.
AEZS' s 10-Year Quick Ratio Range
Min: 1.21  Med: 3.13 Max: 32.71
Current: 4.78
1.21
32.71
Days Sales Outstanding 6.00
AEZS's Days Sales Outstanding is ranked higher than
93% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. AEZS: 6.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
AEZS' s 10-Year Days Sales Outstanding Range
Min: 14.11  Med: 194.78 Max: 19345
Current: 6
14.11
19345

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.33
AEZS's Price/Net Cash is ranked lower than
51% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. AEZS: 6.33 )
Ranked among companies with meaningful Price/Net Cash only.
AEZS' s 10-Year Price/Net Cash Range
Min: 3.31  Med: 12.70 Max: 49
Current: 6.33
3.31
49
Price/Net Current Asset Value 3.80
AEZS's Price/Net Current Asset Value is ranked higher than
71% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. AEZS: 3.80 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AEZS' s 10-Year Price/Net Current Asset Value Range
Min: 2.74  Med: 4.06 Max: 18.38
Current: 3.8
2.74
18.38
Price/Tangible Book 1.36
AEZS's Price/Tangible Book is ranked higher than
90% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. AEZS: 1.36 )
Ranked among companies with meaningful Price/Tangible Book only.
AEZS' s 10-Year Price/Tangible Book Range
Min: 1.69  Med: 2.58 Max: 9.8
Current: 1.36
1.69
9.8
Earnings Yield (Greenblatt) (%) 127.97
AEZS's Earnings Yield (Greenblatt) (%) is ranked higher than
99% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. AEZS: 127.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AEZS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 4.2  Med: 147.20 Max: 3745.9
Current: 127.97
4.2
3745.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AEZ.Canada, ET81.Germany,
AEterna Zentaris Inc is incorporated on September 12, 1990 under the Canada Business Corporations Act (the CBCA) and continues to be governed by the CBCA. The Company is an oncology and endocrinology drug development company investigating treatments for various unmet medical needs. Its pipeline encompasses compounds at all stages of development from drug discovery through to marketed products. Its oncology pipeline also encompasses other earlier-stage programs, including AEZS-112, an oral anticancer agent which involves three mechanisms of action such as tubulin, topoisomerase II and angiogenesis inhibition which has completed a Phase 1 trial in advanced solid tumors and lymphoma. Additionally, several novel targeted anticancer candidates such as AEZS-120, a live recombinant oral tumor vaccine candidate, as well as PI3K/Erk inhibitors, including AEZS-129, AEZS-134 and AEZS-136, are currently in preclinical development. In endocrinology, the Company is preparing the filing of an NDA in the U.S. for the registration of AEZS-130, an oral ghrelin agonist, as a diagnostic test for adult growth hormone deficiency (AGHD). A Phase 3 trial under a SPA with the FDA has been completed in this indication. Furthermore, AEZS-130 is in a Phase 2A trial for the treatment of cancer-induced cachexia.
» More Articles for AEZS

Headlines

Articles On GuruFocus.com
siva Jun 29 2015 
siva Jun 29 2015 
siva Jun 29 2015 
siva Jun 29 2015 
siva Jun 29 2015 
Siva Jun 27 2015 
Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
Can Keryx Succeed Without Partnership? Apr 24 2012 
Keryx Still Has High Potential from Zerenex Apr 12 2012 
comment on AEZS Oct 26 2011 

More From Other Websites
July 29, 2015 Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development Jul 29 2015
Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development Jul 29 2015
Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development Jul 29 2015
July 28, 2015 Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer... Jul 28 2015
7:32 am Aeterna Zentaris announces granting the option to develop and commercialize its live,... Jul 28 2015
Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology Jul 28 2015
Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology Jul 28 2015
July 27, 2015 Aeterna Zentaris Commences Promotional Activities for EMD Serono’s Saizen® Jul 27 2015
Aeterna Zentaris Commences Promotional Activities for EMD Serono's Saizen® Jul 27 2015
Aeterna Zentaris Commences Promotional Activities for EMD Serono's Saizen® Jul 27 2015
The Biotech Rocket is Running Out of Fuel: Three Stocks to Keep You Soaring - Broad Street Alerts Jul 23 2015
Aeterna Zentaris' Endometrial Cancer Study Fully Enrolled - Analyst Blog Jul 01 2015
Ergomed’s Co-Development Partner Aeterna Zentaris Completes Patient Recruitment for ZoptEC Phase 3... Jun 30 2015
June 30, 2015 Aeterna Zentaris Completes Patient Recruitment for ZoptEC Phase 3 Study with... Jun 30 2015
Co-development partner news Jun 30 2015
Aeterna Zentaris Completes Patient Recruitment for ZoptEC Phase 3 Study with Zoptarelin Doxorubicin... Jun 30 2015
Aeterna Zentaris Completes Patient Recruitment for ZoptEC Phase 3 Study with Zoptarelin Doxorubicin... Jun 30 2015
June 25, 2015 Aeterna Zentaris Announces Selection of Ergomed to Conduct Confirmatory Phase 3... Jun 25 2015
Aeterna Zentaris Announces Selection of Ergomed to Conduct Confirmatory Phase 3 Clinical Trial of... Jun 25 2015
June 18, 2015 Aeterna Zentaris Announces Extension to Regain Compliance with NASDAQ's Minimum Bid... Jun 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK